Drug class
Tricyclic-structure anxiolytic; sigma-1 and sigma-2 receptor ligand
Mechanism of action
Unlike conventional tricyclic antidepressants, opipramol has relatively low monoamine-reuptake inhibition and acts predominantly through sigma-1 and sigma-2 receptor interactions, with additional affinity for histamine H1 and other central receptors. These effects modulate central anxiety and somatic symptom pathways.
General use cases
- Treatment of generalised anxiety disorder and somatoform disorders in countries where opipramol is authorised.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
